Product Description
Mechanisms of Action: NK2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Menarini
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Colic
Phase 1: Colic|Intestinal Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12615001364561p |
CASE1620 | N/A |
Not yet recruiting |
Breast Cancer |
None |
|||
NCT00655083 |
NIC 02 | P1 |
Completed |
Colic|Intestinal Diseases |
2009-05-01 |
2019-03-18 |
Treatments |
|
2009-018218-21 |
nocry | P2 |
Completed |
Colic |
2013-12-28 |
2022-03-13 |
Treatments |
|
NCT01258153 |
no-cry | P2 |
Completed |
Colic |
2013-12-01 |
2019-03-19 |
Treatments |
|
NCT01309009 |
nocry-a | P2 |
Withdrawn |
Colic |
2012-11-01 |
2019-03-19 |
Treatments |
|
2010-022706-41 |
NOCRY-a | P2 |
Terminated |
Colic |
2012-10-15 |
2022-03-13 |
Treatments |
|
NCT01532518 |
NIC-04 | P2 |
Completed |
Colic |
2012-07-01 |
2023-05-07 |
||
2006-001524-39 |
2006-001524-39 | P2 |
Completed |
Colic |
2007-01-24 |
2022-03-12 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|